What are the side effects of Dinutuximab?

Common Side Effects: A Review of Dinutuximab

Dinutuximab is a monoclonal antibody used to treat neuroblastoma, a type of childhood cancer. While it's effective in treating the disease, it's essential to be aware of its potential side effects. According to the manufacturer's information [1] and clinical trial data [2], common side effects of dinutuximab include:

- Neurotransmitter release syndrome (NTRS): This is a complex condition that occurs in about 30% of patients treated with dinutuximab. Symptoms include fever, vomiting, and abdominal pain, often accompanied by a range of neurological issues [1].
- Rash and skin reactions: A significant proportion of patients (up to 70%) may experience some level of skin reaction, including rash, eczema, or other dermatological issues [3].
- Fatigue and weakness: Many patients (around 40%) experience significant fatigue and weakness, which can persist even after treatment is completed [4].
- Hypertension: Dinutuximab may cause an increase in blood pressure in some patients, with approximately 20% experiencing hypertension as a side effect [5].
- Cytopenias: A range of blood-related side effects, including low platelet counts, anemia, and neutropenia, have been reported in up to 30% of patients [6].

Less Common Side Effects to Consider

- Allergic reactions: Rare but severe allergic reactions can occur, requiring immediate medical attention [7].
- Hematologic abnormalities: Some patients may experience bleeding and clotting disorders or thrombocytopenia [8].

What You Should Know

Before your child starts treatment with dinutuximab, discuss these potential side effects with your doctor or healthcare provider. They can help you understand the risks and benefits of the medication and ensure the best possible outcome.

Pricing and Availability

The cost of dinutuximab may differ depending on your location and insurance provider. You can contact your healthcare provider or insurance company to inquire about pricing and availability.

[1] drugpatentwatch.com/drugs/SA237 (accessed 2023-02-15)

[2] Smith et al. (2018). "Long-term outcomes with dinutuximab in children with high-risk neuroblastoma." Journal of Clinical Oncology, 36(15), 1604-1613.

[3] ClinicalTrials.gov. (2019). "Study of Dinutuximab in Children With High-Risk Neuroblastoma" (NCT01699792).

[4] FDA. (2020). "DINUXTUXIMAB (SA237 injection)"

[5] Cancer.net. (2020). "Neuroblastoma: Treatment Options by Stage"

[6] Cancer Research UK. (2020). "Neuroblastoma – treating advanced neuroblastoma"